Prognostic value of maternal N‐terminal pro‐B‐type natriuretic peptide for prediction of severe maternal adverse outcome in women with pre‐eclampsia
Open Access
- 8 November 2025
- journal article
- Published by Wiley in Ultrasound in Obstetrics & Gynecology
- Vol. 66 (6) , 754-761
Abstract
Objective: N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP), a marker of cardiac stress, has been proposed as a potential prognostic biomarker for maternal adverse outcome in pre‐eclampsia (PE). This study aimed to evaluate the predictive value of NT‐proBNP for severe maternal adverse outcome in pregnancies with an established diagnosis of PE. Methods: This was a retrospective cohort study of singleton pregnancies diagnosed with PE ≤ 36 weeks of gestation that were assessed at the Medical University of Vienna between January 2018 and December 2023. Maternal serum levels of NT‐proBNP, soluble fms‐like tyrosine kinase‐1 (sFlt‐1) and placental growth factor (PlGF) were measured at the time of PE diagnosis. The primary outcome was the occurrence of a severe maternal adverse event, including intensive care unit admission, maternal death, pulmonary edema and severe neurological complications. Associations between severe maternal adverse outcome and Z ‐scores for NT‐proBNP and the sFlt‐1/PlGF ratio were analyzed using logistic and Cox regression models adjusted for gestational age at sampling and the Z ‐score of the other biomarker. The area under the receiver‐operating‐characteristics (ROC) curve (AUC) was used to assess the discriminative ability of the biomarkers. Results: Of 130 women included in our cohort, 13 (10%) experienced severe maternal adverse outcome. NT‐proBNP levels were significantly higher in this group (median, 688.0 (interquartile range (IQR), 249.6–1038.0) pg/mL vs 106.1 (IQR, 50.6–280.6) pg/mL; P < 0.001). Higher NT‐proBNP Z ‐score was associated significantly with severe maternal adverse outcome (adjusted odds ratio, 3.24 (95% CI, 1.50–7.84); P = 0.005) and predicted shorter time‐to‐delivery with severe maternal adverse outcome (adjusted hazard ratio, 3.08 (95% CI, 1.47–6.44); P = 0.003) after adjusting for gestational age at sampling and sFlt‐1/PlGF ratio Z ‐score. The sFlt‐1/PlGF ratio was not associated significantly with these outcomes. ROC‐curve analysis showed that NT‐proBNP had superior discriminative performance compared with the sFlt‐1/PlGF ratio (AUC, 0.75 (95% CI, 0.61–0.90) vs 0.67 (95% CI, 0.56–0.79)). The performance of both biomarkers improved when combined with gestational age at sampling (AUC, 0.82 (95% CI, 0.71–0.94) vs 0.76 (95% CI, 0.65–0.88)). Conclusion: NT‐proBNP was a strong predictor of severe maternal adverse outcome and time‐to‐delivery in women diagnosed with PE, especially in early‐onset cases. NT‐proBNP may serve as a clinically accessible biomarker for risk stratification and surveillance in women with established PE. © 2025 The Author(s). Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.Keywords
This publication has 41 references indexed in Scilit:
- N‐terminal pro B‐type natriuretic peptide as biomarker to predict pre‐eclampsia and maternal–fetal complicationsUltrasound in Obstetrics & Gynecology, 2025
- Maternal cardiovascular function in midgestation is related to placental angiogenesisUltrasound in Obstetrics & Gynecology, 2024
- Longitudinal assessment of angiogenic markers in prediction of adverse outcome in women with confirmed pre‐eclampsiaUltrasound in Obstetrics & Gynecology, 2023
- The placenta and preeclampsia: villain or victim?American Journal of Obstetrics and Gynecology, 2022
- Angiogenic markers and their longitudinal change for predicting adverse outcomes in pregnant women with chronic hypertensionAmerican Journal of Obstetrics and Gynecology, 2021
- Biomarkers for the diagnosis and management of heart failureHeart Failure Reviews, 2021
- Soluble fms‐like tyrosine kinase‐1 to placental growth factor ratio: ruling out pre‐eclampsia for up to 4 weeks and value of retestingUltrasound in Obstetrics & Gynecology, 2019
- Pre‐eclampsia and the cardiovascular–placental axisUltrasound in Obstetrics & Gynecology, 2018
- N-terminal pro B-type natriuretic peptide and angiogenic biomarkers in the prognosis of adverse outcomes in women with suspected preeclampsiaClinica Chimica Acta, 2016
- Global and regional estimates of preeclampsia and eclampsia: a systematic reviewEuropean Journal of Obstetrics & Gynecology and Reproductive Biology, 2013